Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

February 22, 2019

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2029

Conditions
Metastatic Tumors
Interventions
RADIATION

Palliative Radiation

Investigators should follow the principles of palliative radiotherapy as per the individual institution in order to alleviate symptoms or prevent complications. If radiotherapy is indicated, recommended doses are 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.

DRUG

Chemotherapy

Chemotherapy may be given as indicated.

DRUG

Immunotherapy

Immunotherapy may be given as indicated.

DRUG

Hormones

Hormones may be given as indicated.

OTHER

Observation

Observation only is acceptable if this is the standard practice.

RADIATION

Stereotactic Ablative Radiotherapy

Total dose of radiation and number of fractions will depend on the site of disease. Doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every 2 days), or 35 Gy in 5 fractions (daily).

Trial Locations (14)

3181

Alfred Health, Melbourne

8091

University Hospital of Zürich, Zurich

V8R 4X1

BC Cancer Agency, Vancouver Island Centre, Victoria

B3S 0H6

Nova Scotia Health Authortiy, Halifax

P3E 5J1

Health Sciences North, Greater Sudbury

N2G 1G3

Grand River Hospital, Kitchener

N6A 5W9

London Regional Cancer Program of the Lawson Health Research Institute, London

L5M 2N1

Trillium Health Partners-Credit Valley Hospital, Mississauga

L2S 0A9

Niagra Health System, St. Catharines

M5G 2C4

University Health Network, Toronto

H2X 0C1

Centre hospitalier de l'Université de Montréal-CHUM, Montreal

Unknown

VU University Medical Centre, Amsterdam

EH4 2XU

Western General Hospital, Edinburgh

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

Sponsors
All Listed Sponsors
collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

collaborator

British Columbia Cancer - Centre for the North

UNKNOWN

collaborator

Beaston West of Scotland Cancer Centre

UNKNOWN

collaborator

London Health Sciences Centre

OTHER

lead

David Palma

OTHER